A5036004952- Ophthalmology and Eye Disorders
- Pituitary Gland Disorders and Treatments
- Thyroid Disorders and Treatments
- Glaucoma and retinal disorders
- Growth Hormone and Insulin-like Growth Factors
- Advanced Differential Geometry Research
- Sympathectomy and Hyperhidrosis Treatments
- Retinal Development and Disorders
- Ocular Diseases and Behçet’s Syndrome
- Facial Trauma and Fracture Management
- Child Abuse and Related Trauma
- Ophthalmology and Visual Impairment Studies
- Vestibular and auditory disorders
- Migraine and Headache Studies
- Ocular Surface and Contact Lens
- Economic and Social Issues
- Lymphoma Diagnosis and Treatment
- Retinal Diseases and Treatments
- Thyroid Cancer Diagnosis and Treatment
- Nasal Surgery and Airway Studies
- Facial Rejuvenation and Surgery Techniques
- Retinal and Optic Conditions
- Ocular Oncology and Treatments
- Nasolacrimal Duct Obstruction Treatments
- Erythrocyte Function and Pathophysiology
Essen University Hospital
2016-2025
University of Duisburg-Essen
2015-2025
Ophthalmology Clinic
2017-2024
Universitätsklinik für Augenheilkunde
2004-2024
Düsseldorf University Hospital
2023
Heinrich Heine University Düsseldorf
2023
National Center for Tumor Diseases
2023
LVR-Klinik Köln
2021
Augenklinik Heidelberg
1924-2020
Augenklinik Universitätsklinikum Würzburg
2007
Graves' orbitopathy (GO) is the main extrathyroidal manifestation of disease, though severe forms are rare. Management GO often suboptimal, largely because available treatments do not target pathogenic mechanisms disease. Treatment should rely on a thorough assessment activity and severity its impact patient's quality life. Local measures (artificial tears, ointments dark glasses) control risk factors for progression (smoking thyroid dysfunction) recommended all patients. In mild GO,...
Summary of consensus a. All patients with GO should (Fig. 1):Be referred to specialist centers;Be encouraged quit smoking;Receive prompt treatment in order restore andmaintain euthyroidism.b. Patients sight-threatening be treatedwith i.v. GCs as the first-line treatment; if responseis poor after 1–2 weeks, they submitted tourgent surgical decompression.c. The choice for moderate-to-severe isi.v. (with or without OR) orbitopathy isactive;surgery(orbitaldecompression,squintsurgery,and/or eyelid...
Graves' orbitopathy (GO) is the main extrathyroidal manifestation of disease (GD). Choice treatment should be based on assessment clinical activity and severity GO. Early referral to specialized centers fundamental for most patients with Risk factors include smoking, thyroid dysfunction, high serum level thyrotropin receptor antibodies, radioactive iodine (RAI) treatment, hypercholesterolemia. In mild active GO, control risk factors, local treatments, selenium (selenium-deficient areas) are...
Thyroid eye disease is a debilitating, disfiguring, and potentially blinding periocular condition for which no Food Drug Administration-approved medical therapy available. Strong evidence has implicated the insulin-like growth factor I receptor (IGF-IR) in pathogenesis of this disease.In randomized, double-masked, placebo-controlled, phase 3 multicenter trial, we assigned patients with active thyroid 1:1 ratio to receive intravenous infusions IGF-IR inhibitor teprotumumab (10 mg per kilogram...
The objective of this study was to examine whether TSH-receptor antibody [TSH binding inhibitory antibodies (TBII)] levels are associated with the severity Graves' ophthalmopathy (GO) over entire course disease.A total 159 patients GO were followed for 12-24 months. One year after first symptoms GO, all classified into mild or severe according their clinical manifestations. TBII measured every 3 months onset GO. Receiver operating characteristic plot analysis performed assess power...
To evaluate teprotumumab safety/efficacy in patients with thyroid eye disease (TED) who were nonresponsive or experienced a flare.The Treatment of Graves' Orbitopathy to Reduce Proptosis Teprotumumab Infusions an Open-Label Clinical Extension Study (OPTIC-X) is treatment and re-treatment trial following the placebo-controlled Phase 3 (Thyroid Eye Disease) Randomized, Placebo-Controlled, (OPTIC) trial.Patients previously received placebo (n = 37) 14) OPTIC.OPTIC nonresponders those flared...
Hyperthyroidism caused by Graves’ disease (GD) is a relatively rare in children. Treatment options are the same as adults – antithyroid drugs (ATD), radioactive iodine (RAI) or thyroid surgery, but risks and benefits of each modality different. The European Thyroid Association guideline provides new recommendations for management pediatric GD with without orbitopathy. Clinicians should be alert that may present behavioral changes declining academic performance Measurement serum TSH receptor...
In patients with Graves' disease, smoking considerably increases the incidence and severity of thyroid associated ophthalmopathy (TAO). The authors sought to determine if also influences course TAO during treatment, efficacy therapy.41 smokers 19 non-smokers moderate untreated were included in this prospective study. All treated steroids and, 6 weeks after beginning drug therapy, orbital irradiation. Follow up was performed 1.5, 4.5, 7.5, 12 months Proptosis, clinical activity score (CAS),...
<h3>Aim:</h3> To compare the outcome of various surgical approaches orbital decompression in patients with Graves' orbitopathy (GO) receiving surgery for disfiguring proptosis. <h3>Method:</h3> Data forms and questionnaires from consecutive, euthyroid inactive GO who had undergone proptosis 11 European centres were analysed. <h3>Results:</h3> Eighteen different (combinations of) used, swinging eyelid approach being most popular followed by coronal transconjunctival approaches. The average...
Graves' orbitopathy (GO) is an autoimmune condition, which associated with poor clinical outcomes including impaired quality of life and socio-economic status. Current evidence suggests that the incidence GO in Europe may be declining, however data on prevalence this disease are sparse. Several variants exist, euthyroid GO, recently listed as a rare (ORPHA466682). The objective was to estimate its Europe, based available literature, consider whether they potentially qualify rare. Recent...
<h3>Background and aims:</h3> Retrospective, observational study to compare clinical symptoms TSH-receptor antibodies (TRAb) in Graves ophthalmopathy (GO) euthyroid primarily hypothyroid patients those hyperthyroid patients. <h3>Methods:</h3> Clinical (NOSPECS (severity) CAS (activity) score), prevalence levels of thyroid specific the course disease were evaluated 143 hyperthyroid, 28 11 with GO. <h3>Results:</h3> Patients euthyroid/hypothyroid GO developed significantly less severe score...
<h3>Background/aims</h3> The epidemiology of Graves’ orbitopathy (GO) may be changing. aim the study was to identify trends in presentation GO tertiary centres and initial management over time. <h3>Methods</h3> Prospective observational European Group On Orbitopathy (EUGOGO) centres. All new referrals with a diagnosis 4-month period 2012 were included. Clinical demographic characteristics, referral timelines decisions about recorded. data compared similar EUGOGO survey performed 2000....
Variation in induced models of autoimmunity has been attributed to the housing environment and its effect on gut microbiota. In Graves' disease (GD), autoantibodies thyrotropin receptor (TSHR) cause autoimmune hyperthyroidism. Many GD patients develop orbitopathy or ophthalmopathy (GO) characterized by orbital tissue remodeling including adipogenesis. Murine GD/GO would help delineate pathogenetic mechanisms, although several have reported, most lack reproducibility. A model comprising...
Graves' disease (GD) is an autoimmune condition in which autoantibodies to the thyrotropin receptor (TSHR) cause hyperthyroidism. About 50% of GD patients also have orbitopathy (GO), intractable expansion orbital contents causes diplopia, proptosis and even blindness. Murine models GD/GO, developed different centres, demonstrated significant variation gut microbiota composition correlated with TSHR-induced heterogeneity. To investigate whether correlation indicates causation, we modified...
Risdiplam is a survival of motor neuron 2 (SMN2) splicing modifier for the treatment patients with spinal muscular atrophy (SMA). The JEWELFISH study (NCT03032172) was designed to assess safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) risdiplam in previously treated pediatric adult types 1–3 SMA. Here, an analysis performed after all had received at least 1 year risdiplam. Patients confirmed diagnosis 5q-autosomal recessive SMA between ages 6 months 60 years were...
Abstract Context Gut bacteria can influence host immune responses but little is known about their role in tolerance-loss mechanisms Graves disease (GD; hyperthyroidism caused by autoantibodies, TRAb, to the thyrotropin receptor, TSHR) and its progression orbitopathy (GO). Objective This work aimed compare fecal microbiota GD patients, with GO of varying severity, healthy controls (HCs). Methods Patients were recruited from 4 European countries (105 41 HCs) for an observational study...
Abstract Context Inhibition of the neonatal fragment crystallizable receptor (FcRn) reduces pathogenic thyrotropin antibodies (TSH-R-Ab) that drive pathology in thyroid eye disease (TED). Objective We report first clinical studies an FcRn inhibitor, batoclimab, TED. Design Proof-of-concept (POC) and randomized, double-blind placebo-controlled trials. Setting Multicenter. Participants Patients with moderate-to-severe, active Intervention In POC trial, patients received weekly subcutaneous...
Introduction Graves’ disease (GD) is an autoimmune disorder caused by autoantibodies against the thyroid stimulating hormone receptor (TSHR) leading to overstimulation of gland. Thyroid eye (TED) most common extra thyroidal manifestation GD. Therapeutic options treat TED are very limited and novel treatments need be developed. In present study we investigated effect linsitinib, a dual small-molecule kinase inhibitor insulin-like growth factor 1 (IGF-1R) Insulin (IR) on outcome GD TED....
We evaluated the relationship between ocular surface damage, elevated lid aperture/impaired Bell's phenomenon and reduced tear production in thyroid-associated ophthalmopathy (TAO). Suspecting a possible role of autoantibodies specific for TSH receptor (TSHR), we further investigated TSHR expression healthy lacrimal gland (LG).A total 48 patients with active TAO 26 controls were examined basal secretion, Rose Bengal fluorescein staining, impression cytology (IPC), break-up time (BUT),...
Graves' disease (GD) is maintained by stimulating antibodies against the TSH receptor. orbitopathy (GO) main extrathyroidal manifestation of GD, potentially involving autoimmunity IGF1 receptor (IGF1R).We tested for autoantibodies IGF1R (IGF1R-Abs) in sera GD patients and controls elucidated their possible implication disease.A diagnostic assay IGF1R-Ab was established with recombinant human as autoantigen. Serum samples or purified Ig preparations were analyzed binding modulation signaling...